Back to Natera

Natera News

NTRA

Natera Appoints Independent Director Thomas Lynch

Natera (NTRA) appoints Thomas Lynch as an independent director, expanding its board to 12 members. Governance and investor implications on 06/05/2026.

5 June 2026Natera, Inc.
NTRA

Natera (NTRA) Q4 & FY2025 Results

Natera (NTRA) files 8‑K with Q4 & FY2025 results and 2026 outlook. Net loss $208.2M, cash $1.076B, operating cash flow $215.3M; Signatera, reimbursement risks.

26 February 2026Natera, Inc.
NTRA

Natera Acquires Foresight Diagnostics (NTRA)

Natera (NTRA) expands oncology testing with Foresight acquisition announced Dec 4, 2025—strengthens Signatera MRD IP and tumor-informed testing.

5 December 2025Natera, Inc.
NTRA

Natera Q3 2025: Revenue Up 34.7%, Guidance Raised

Natera (NTRA) reports 34.7% revenue growth in Q3 2025, product revenues $590.2M of $592.2M, and raises 2025 guidance; Signatera drives momentum amid reimbursement and regulatory risks.

6 November 2025Natera, Inc.
All news